Is it an era for statin for life?

Size: px
Start display at page:

Download "Is it an era for statin for life?"

Transcription

1 Is it an era for statin for life? Mohamed Abdel Ghany Professor of Cardiology Cairo University Cardiovascular Disease (CVD) is the leading global cause of death 1

2 Dyslipidemia as a main Risk Factor for Cardiovascular Disease INTERHEART: Impact of multiple risk factors on CV risk Design Participants Objective Large international case-control study 12,461 cases; 14,637 controls; 52 countries To determine association of first MI with: Smoking Lipids Hypertension Diabetes Obesity Diet Physical Alcohol Psychosocial activity consumption factors* Follow-up 4 years, February 1999 March Odds ratio for 1st MI (99% CI) Smk = smoking DM = diabetes Smk HTN = hypertension (1) Obes = obesity Ps = psychosocial factors Note: odds ratio plotted on a doubling scale DM (2) HTN (3) ApoB- All 4 All 4 ApoA1 + Obes (4) All 4 + Ps All risk factors Yusuf S et al. Lancet. 2004;364:

3 Total Cholesterol Distribution: CHD vs Non-CHD Population Framingham Heart Study 26-Year Follow-up No CHD 35% of CHD Occurs in People with TC<200 mg/dl CHD Total Cholesterol (mg/dl) Castelli WP. Atherosclerosis. 1996;124(suppl):S1-S Reprinted with permission from Elsevier Science. On-Treatment LDL-C is Closely Related to CHD Events in Statin Trials Lower is Better JUPITER study included for reference only; event rate at 4.5 years, lipid changes at 2 years Rx - Statin therapy PRA - pravastatin ATV - atorvastatin 4S Rx Secondary Prevention 4S Placebo LIPID Placebo 15 LIPID Rx CARE - Placebo 10 CARE Rx CORONA - Placebo CORONA Rx HPS Placebo Primary Prevention HPS - Rx TNT ATV10 TNT ATV80 PROVE-IT PRA WOSCOPS Placebo JUPITER Placebo PROVE-IT ATV AFCAPS Placebo 6 5 AFCAPS Rx WOSCOPS Rx JUPITER Rx ASCOT Rx ASCOT Placebo 0 40 (1.0) 60 (1.6) (2.1) (2.6) (3.1) (3.6) LDL-C achieved mg/dl (mmol/l) 160 (4.1) 180 (4.7) 200 (5.2) Adapted from Rosensen RS. Exp Opin Emerg Drugs 2004; 9(2): LaRosa JC et al. N Engl J Med 2005; 352: Ridker PM et al. NEJM 2008; 359: Rosuvastatin Slide Kit Feb 2012 [6] 3

4 Proportional reduction in event rate (% SE) Proportional reduction in event rate (% SE) 22/01/2017 Relationship Between Proportional Reduction in Events and Mean LDL-C Reduction at 1 Year A prospective meta-analysis of data from 90,056 individuals from 14 statin trials A 1 mmol/l (39 mg/dl) reduction in LDL-C was associated with a 50 23% reduction in major coronary events 50 21% reduction in major vascular events (19) 1.0 (38) 1.5 (58) 2.0 (77) -10 Reduction in LDL-C mmol/l (mg/dl) (19) 1.0 (38) 1.5 (58) 2.0 (77) Reduction in LDL-C mmol/l (mg/dl) CTT Collaborators. Lancet 2005; 366: Rosuvastatin Slide Kit Feb 2012 [7] More versus Less Intensive Statin Treatment is Associated with Further Reductions in Major Vascular Events 0.51 mmol/l further reduction in LDL-C with more intensive statin therapy 2-3 mmol/l further reduction in LDL-C with more intensive statin therapy 15% additional reduction in major vascular events (p<0.0001) 40-50% additional reduction in major vascular events (p<0.0001) CTT Collaborators. Lancet 2010; 376: Rosuvastatin Slide Kit Feb 2012 [8] 4

5 9 Overview on Dyslipidemia Management in Egypt Rosuvastatin Slide Kit Dec Feb [9] Centralized Pan-Middle East Survey on the Under-Treatment of Hypercholesterolemia: Results from the CEPHEUS Study in Egypt Primary Objectives: To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III. Study Design: This was a multi-centre, observational study of 1043 patients (18 years old or above) receiving lipid-lowering pharmacological treatment for at least 3 months and with no dose change for a minimum of 6 weeks. Reda A, Abdel-Rehim AA, Etman A, Afifi OS. Cardiol Ther Nov 18 Rosuvastatin Slide Kit Feb 2012 [10] 5

6 % of patients Achieving LDL Goals 22/01/2017 Only 32.5% of Treated Patients Achieved Treatment Goals* 80.0% 70.0% 66.5% 71.1% 60.0% 72.4% of CEPHEUS Population 50.0% 40.0% 30.0% 34.3% 20.0% 10.0% 10.7% 7.9% 0.0% Very high High but not very high *2004 updated NCEP ATP III Reda A, Abdel-Rehim AA, Etman A, Afifi OS. Cardiol Ther Nov 18 Medium high Medium low Low Risk Level Rosuvastatin Slide Kit Feb 2012 [11] How can we manage dyslipidemia in according to LATEST Guidelines? 6

7 2013 ACC/AHA Cholesterol Treatment Guideline Recommendations Focus on ASCVD Risk Reduction: 4 statin benefit groups* Clinical ASCVD LDL-level 190 mg/dl Diabetes, aged years, with LDL-C mg/dl Estimated 10-year risk of ASCVD of 7.5%, years of age, and with LDL-C mg/dl * Moderate- or high-intensity statin therapy recommended for these 4 groups Clinical ASCVD defined as acute coronary syndromes, history of MI, stable or unstable angina, coronary or arterial revascularization, stroke, transient ischemic attacks, or peripheral artery disease Estimated using Pooled Cohort Risk Assessment Equations Stone NJ, et al. J Am Coll Cardiol. 2013: doi: /j.jacc Available at: Accessed November 13,

8 Intensity of Statin Therapy High-Intensity Statin Therapy Moderate-Intensity Stain Therapy Low-Intensity Statin Therapy LDL C 50% LDL C 30% to <50% LDL C <30% Atorvastatin (40 ) 80 mg Rosuvastatin 20 (40) mg Atorvastatin 10 (20) mg Rosuvastatin (5) 10 mg Simvastatin mg Pravastatin 40 (80) mg Lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg bid Pitavastatin 2 4 mg Simvastatin 10 mg Pravastatin mg Lovastatin 20 mg Fluvastatin mg Pitavastatin 1 mg Lifestyle modification remains a critical component of ASCVD risk reduction, both prior to and in concert with the use of cholesterol lowering drug therapies. Statins/doses that were not tested in randomized controlled trials (RCTs) reviewed are listed in italics Evidence from 1 RCT only: down-titration if unable to tolerate atorvastatin 80 mg in IDEAL Initiation of or titration to simvastatin 80 mg not recommended by the FDA due to the increased risk of myopathy, including rhabdomyolysis. Stone NJ, et al. J Am Coll Cardiol. 2013: doi: /j.jacc Available at: Accessed November 13, ACC Expert consensus decision updates Patients 21 Years of Age with Stable Clinical ASCVD without Comorbidities, on Statin for Secondary Prevention Patients 21 Years of Age with Clinical ASCVD with Comorbidities, on Statin for Secondary Prevention Patient has 50% LDL- C reduction (may consider LDL-C <100 mg/dl) on maximally tolerated statin J Am Coll Cardiol Jul 5;68(1): doi: /j.jacc Epub 2016 Apr 1. Patient has 50% LDL-C reduction (may consider LDL-C <70 mg/dl or may consider non-hdl-c <100 mg/dl in patients with diabetes) on maximally tolerated statin 8

9 2016 ESC/EAS Guidelines for the management of dyslipidaemias The Task Force of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Task Force Members: A L. Catapano* (Chairperson) (Italy), I Graham* (Chairperson) (Ireland), G De Backer (Belgium), O Wiklund (Sweden), M. J Chapman (France), H Drexel (Austria), A W. Hoes (The Netherlands), C S. Jennings (UK), U Landmesser (Germany), T R. Pedersen (Norway), Ž Reiner (Croatia), G Riccardi (Italy), M-R Taskinen (Finland), L Tokgozoglu (Turkey), W. M. M Verschuren (The Netherlands), Ch Vlachopoulos (Greece), D A. Wood (UK), J L Zamorano (Spain). Additional Contributor: M T Cooney (Ireland) Alberico L. Catapano et al. Eur Heart J 2016;eurheartj.ehw272 Very high-risk High-risk: Moderate-risk: Low-risk: Risk Categories Subjects with any of the following: Documented CVD*. DM with target organ damage or with a major risk factor Severe CKD (GFR <30 ml/min/1.73 m2). A calculated SCORE 10% for 10-year risk of fatal CVD. Subjects with: Markedly elevated single risk factors Most other people with DM Moderate CKD (GFR ml/min/1.73 m2). A calculated SCORE 5% and <10% for 10- year risk of fatal CVD. SCORE is 1% and <5% for 10-year risk of fatal CVD. SCORE <1% for 10-year risk of fatal CVD. Adapted from Alberico L. Catapano et al. Eur Heart J 2016;eurheartj.ehw272 9

10 Alberico L. Catapano et al. Eur Heart J 2016;eurheartj.ehw272 Crestor Role in Dyslipidemia from Efficacy to Cardio Protection Greatest effects on the atherogenic lipid profile and beneficial changes on inflammatory markers Profound benefits on atherosclerosis Greatest reductions in cardiovascular morbidity and mortality Schuster H. Expert Rev Cardiovasc Ther 2007;5(2):

11 Studies Atherogenic lipid profile +/ inflammatory markers Atherosclerosis Cardiovascular morbidity & mortality Stellar METEOR JUPITER STELLAR: Study Design 6-week dietary lead-in period LDL-C 160 mg/dl and <250 mg/dl TG <400 mg/dl 18 years 6-week active treatment CRESTOR (rosuvastatin calcium) (480 patients) Atorvastatin (641 patients) 10 mg 20 mg 40 mg 10 mg 20 mg 40 mg 80 mg The primary endpoint was the percent change in LDL-C from baseline to 6 weeks Simvastatin (655 patients) 10 mg 20 mg 40 mg 80 mg CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Pravastatin (492 patients) 10 mg 20 mg 40 mg Adapted from Jones PH, et al. Am J Cardiol. 2003;92:

12 LDL-C ( SE) Reduction (%) HDL-C Increase (%) 22/01/2017 STELLAR Percentage Change in LDL-C 0 CRESTOR (mg) Atorvastatin (mg) Simvastatin (mg) Pravastatin (mg) * STELLAR Percentage Change from Baseline in HDL-C at Week * CRESTOR (mg) Atorvastatin (mg) Simvastatin (mg) Pravastatin (mg) Jones PH, et al. Am J Cardiol. 2003;92:

13 Patients reaching LDL-C <100 mg/dl (%) 22/01/2017 STELLAR: Percentage of Patients Achieving an LDL-C of <100 mg/dl * CRESTOR (rosuvastatin calcium) Atorvastatin Simvastatin Pravastatin (n=473) (n=633) (n=648) (n=485) 8 14 Adapted from: McKenney JM, et al. Curr Med Res Opin. 2003;19: Impact on atherosclerosis progression 13

14 Change in IMT of 12 carotid sites (mm) mm/yr 22/01/2017 Effects of Rosuvastatin on Carotid IMT Measured using B-mode Ultrasound METEOR Study Design Patients (n=984) Asymptomatic for CHD Rosuvastatin 40 mg (n=702) Maximum IMT 1.2 <3.5 mm Modest hypercholesterolaemia Placebo (n=282) Men (aged 45 70) Women (aged 55 70) Visit: Week: Run-in/eligibility Lipids Safety Lipids Safety CIMT Safety CIMT Safety Lipids Safety CIMT Safety randomised, double-blind, placebo-controlled, parallel-group, multicentre phase III study to determine whether rosuvastatin 40 mg could slow the progression of atherosclerosis among asymptomatic patients assessed as being at low risk of CHD. 1 CIMT Lipids Safety Crouse JR et al. JAMA 2007; 297: CIMT=carotid intima media thickness TREATING DYSLIPIDAEMIA WITH CRESTOR SHOWN TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS 1 METEOR Study suggests that development of atherosclerosis can be slowed, even in lowrisk asymptomatic patients PROGRESSION Change in carotid intima media thickness (CIMT) at 2 years 1 Placebo -48% LDL-C +8% HDL-C CRESTOR 40 mg 2 YEARS CRESTOR Time (years) mm/yr 2 * Change in CIMT (95% CI) Placebo n=252 CRESTOR 40 mg n=624 REGRESSION Adapted from Crouse JR, et al. JAMA : REFERENCE: 1. Crouse JR, et al. JAMA :

15 Crestor is approved to slow the progression of atherosclerosis a thickening of the artery wall due to the buildup of cholesterol and other fatty materials. ncements/ucm htm JUPITER Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin Please see slide 28 for Summary of Product Characteristics Ridker P et al. N Eng J Med 2008;359:

16 Change from baseline (%) 22/01/2017 JUPITER study design No history of CAD men 50 yrs women 60 yrs LDL-C <130 mg/dl CRP 2.0 mg/l Placebo run-in Rosuvastatin 20 mg (n=8901) Placebo (n=8901) Visit: Week: monthly Final Lead-in/ eligibility Randomisation Lipids CRP Tolerability Lipids CRP Tolerability Median follow-up 1.9 years Lipids CRP Tolerability HbA 1C CAD=coronary artery disease; LDL-C=low-density lipoprotein cholesterol; CRP=C-reactive protein; HbA 1c=glycated haemoglobin Ridker P et al. N Eng J Med 2008;359: JUPITER Effects on LDL-C, HDL-C, TG and hscrp at 12 months; Percentage change between rosuvastatin and placebo 10 LDL-C HDL-C TG hscrp % p<0.001* 17% p< % p< % p<0.001 *P-value at study completion (48 months) = 0.34 Ridker P et al. N Eng J Med 2008;359:

17 Cumulative Incidence Cumulative Incidence 22/01/2017 Time to First Major Cardiovascular Event with Rosuvstatin versus Placebo 0.08 Results from JUPITER Hazard ratio 0.56 (95% CI ) p< Placebo RRR 44% Rosuvastatin 20 mg 0.02 NNT for 2 y=95 4 y=31 5 y*=25 *Extrapolated figure based on Altman and Andersen method Number at Risk Follow-up (years) Rosuvastatin Placebo Ridker PM et al. NEJM 2008; 359: JUPITER: Fatal or Nonfatal Myocardial Infarction Rosuvastatin Placebo Number of events HR 0.46 (95% CI ) P< RRR 54% Follow-up Years 17

18 Cumulative Incidence, % Cumulative Incidence, % 22/01/2017 JUPITER: Bypass Surgery or PTCA / Hospitalization for UA 6 Rosuvastatin Placebo Number of events HR 0.53 (95% CI ) P< RRR 47% Follow-up Years Number at Risk Rosuvastatin8,901 8,640 8,426 6,550 3,905 1,966 1, Placebo 8,901 8,641 8,390 6,542 3,895 1,977 1, JUPITER: Fatal or Nonfatal Stroke 3 Rosuvastatin Placebo Number of events HR 0.52 (95% CI ) P=0.002 RRR 48% Follow-up Years 18

19 Cumulative Incidence, % 22/01/2017 JUPITER: Death from Any Cause 7 Rosuvastatin Placebo Number of events HR 0.80 (95% CI ) P=0.021 RRR 20% Number at risk Years Rosuvastatin Placebo Post hoc analyses of JUPITER in High Risk Patients Reduction in major CV events with rosuvastatin 20 mg compared to placebo Relative Risk Reduction in event rate RRR 50% 2 RRR 43% 2 Framingham score >20% 2 Absolute risk reduction in event rate: 8.8 per 1000 patient years 1 CV death, stroke and MI P=0.028 (vs placebo) EU score 5% 2 Absolute risk reduction in event rate: 5.1 per 1000 patient years 1 CV death, stroke and MI P= (vs placebo) combined end-point of cardiovascular death, stroke and myocardial infarction 1. CRESTOR, Summary of Product Characteristics. 2. Koenig W, Ridker PM. Eur Heart J (2011) 32, 75 83; doi: /eurheartj/ehq370. Reproduced by permission of Oxford University Press 19

20 JUPITER: Number Needed to Treat (5 year) Endpoint All FRS 10 FRS>10 Primary Endpoint Primary Endpoint, Mortality MI, Stroke, CABG/PTCA, Death MI, Stroke, Death Benchmarks: Statins for hyperlipidemia 5-year NNT Diuretics 5-year NNT Beta-blockers 5-year NNT Aspirin Men 5-year NNT Aspirin Women 5-year NNT Ridker et al. Circulation CV Qual Outcomes 2009;2: Consider Statins a lifelong commitment You may think that once your cholesterol goes down, you can stop taking medication. But, if your cholesterol levels have decreased after you take a Statin, you'll likely need to stay on it indefinitely. If you stop taking it, your cholesterol levels will probably go back up last accessed 25/2/

21 Summary Ischemic heart disease is the leading cause of death globally Dyslipidemia is a major risk factor for ISH. CEPHEUS showed a big gap in Dyslipidemia management in Egypt. Crestor provides high efficacy on Lipid parameters Crestor shown to slow progression of atherosclerosis and provides the optimum cardio protection. Crestor For Life Thank you 21

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY

THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Review of guidelines for management of dyslipidemia in diabetic patients

Review of guidelines for management of dyslipidemia in diabetic patients 2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

New Guidelines in Dyslipidemia Management

New Guidelines in Dyslipidemia Management The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical

More information

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary

More information

Introduction. Objective. Critical Questions Addressed

Introduction. Objective. Critical Questions Addressed Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:

More information

New Guidelines in Dyslipidemia Management

New Guidelines in Dyslipidemia Management The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical

More information

ATP IV: Predicting Guideline Updates

ATP IV: Predicting Guideline Updates Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations

More information

Dyslipedemia New Guidelines

Dyslipedemia New Guidelines Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Long-Term Complications of Diabetes Mellitus Macrovascular Complication Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent

More information

CLINICAL OUTCOME Vs SURROGATE MARKER

CLINICAL OUTCOME Vs SURROGATE MARKER CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical

More information

How to Reduce Residual Risk in Primary Prevention

How to Reduce Residual Risk in Primary Prevention How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with

More information

Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice

Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP

More information

An update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine

An update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal

More information

Dyslipidemia in women: Who should be treated and how?

Dyslipidemia in women: Who should be treated and how? Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European

More information

Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist

Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist 1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in

More information

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor

More information

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now? Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl

More information

What do the guidelines say about combination therapy?

What do the guidelines say about combination therapy? What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,

More information

Landmark Clinical Trials.

Landmark Clinical Trials. Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug

More information

LDL cholesterol and cardiovascular outcomes?

LDL cholesterol and cardiovascular outcomes? LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary

More information

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,

More information

Young high risk patients the role of statins Dr. Mohamed Jeilan

Young high risk patients the role of statins Dr. Mohamed Jeilan Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures

More information

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the

More information

Lipid Panel Management Refresher Course for the Family Physician

Lipid Panel Management Refresher Course for the Family Physician Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new

More information

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment

More information

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD 2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:

More information

Lipid Management 2013 Statin Benefit Groups

Lipid Management 2013 Statin Benefit Groups Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date

More information

Lessons from Recent Atherosclerosis Trials

Lessons from Recent Atherosclerosis Trials Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD

More information

Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals

Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia

More information

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. 2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality

More information

The TNT Trial Is It Time to Shift Our Goals in Clinical

The TNT Trial Is It Time to Shift Our Goals in Clinical The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia

More information

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for + Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics

More information

The Clinical Unmet need in the patient with Diabetes and ACS

The Clinical Unmet need in the patient with Diabetes and ACS The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge

More information

Environmental. Vascular / Tissue. Metabolics

Environmental. Vascular / Tissue. Metabolics Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood

More information

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice 2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine

More information

REAL-CAD. : Cardiovascular benefit of pitavastatin in stable coronary artery disease

REAL-CAD. : Cardiovascular benefit of pitavastatin in stable coronary artery disease REAL-CAD : Cardiovascular benefit of pitavastatin in stable coronary artery disease Soo-Joong Kim M.D., PhD. Department of Cardiology, Internal Medicine, Kyung Hee University Hospital I have nothing to

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by

More information

PCSK9 Agents Drug Class Prior Authorization Protocol

PCSK9 Agents Drug Class Prior Authorization Protocol PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical

More information

Changing lipid-lowering guidelines: whom to treat and how low to go

Changing lipid-lowering guidelines: whom to treat and how low to go European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,

More information

LAMIS (Livalo in AMI Study)

LAMIS (Livalo in AMI Study) JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia

More information

Cholesterol Management Roy Gandolfi, MD

Cholesterol Management Roy Gandolfi, MD Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians

More information

Contemporary management of Dyslipidemia

Contemporary management of Dyslipidemia Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that

More information

The Clinical Debates

The Clinical Debates The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University

More information

Imaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006

Imaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Imaging Biomarkers: utilisation for the purposes of registration EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Vascular Imaging Technologies Carotid Ultrasound-IMT IVUS-PAV QCA-% stenosis 2 ICH E

More information

Learning Objectives. Patient Case

Learning Objectives. Patient Case Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations

More information

New Cholesterol Guidelines What the LDL are we supposed to do now?!

New Cholesterol Guidelines What the LDL are we supposed to do now?! New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013

More information

Modern Lipid Management:

Modern Lipid Management: Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)

More information

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate

More information

Is Lower Better for LDL or is there a Sweet Spot

Is Lower Better for LDL or is there a Sweet Spot Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,

More information

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical

More information

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy? Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists

More information

4 th and Goal To Go How Low Should We Go? :

4 th and Goal To Go How Low Should We Go? : 4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu

More information

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. 2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality

More information

Traitements associés chez l hypertendu: Statines, Aspirine

Traitements associés chez l hypertendu: Statines, Aspirine Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact

More information

LDL and the Benefits of Statin Therapy

LDL and the Benefits of Statin Therapy LDL and the Benefits of Statin Therapy Allan Sniderman McGill University ACC/AHA did not recommend a target-based approach. Right? P 2899 The Expert Panel was unable to find any RCTs that evaluated titration

More information

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant

More information

Weigh the benefit of statin treatment: LDL & Beyond

Weigh the benefit of statin treatment: LDL & Beyond Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University

More information

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine

More information

Robyn Cruz, PharmD, BCPS, BCPP 1

Robyn Cruz, PharmD, BCPS, BCPP 1 Robyn Cruz, PharmD, BCPS, BCPP ISHP Spring Meeting April 2014 Identify major changes in treating hyperlipidemia according to the 2013 ACC/AHA Blood Cholesterol Guidelines Discuss clinical trial data that

More information

Sanger Heart & Vascular Institute Symposium 2015

Sanger Heart & Vascular Institute Symposium 2015 Sanger Heart & Vascular Institute Symposium 2015 Cardiovascular Update For Primary Care Physicians William E. Downey, MD FACC FSCAI Medical Director, Interventional Cardiology Sanger Heart & Vascular Institute

More information

Curriculum Vitae Name : Prof. DR. Dr. Idrus Alwi SpPD, K-KV, FACC, FESC, FAPSIC, FINASIM, FACP. Current Position : Professor of Internal Medicine,

Curriculum Vitae Name : Prof. DR. Dr. Idrus Alwi SpPD, K-KV, FACC, FESC, FAPSIC, FINASIM, FACP. Current Position : Professor of Internal Medicine, Curriculum Vitae Name : Prof. DR. Dr. Idrus Alwi SpPD, K-KV, FACC, FESC, FAPSIC, FINASIM, FACP. Current Position : Professor of Internal Medicine, Faculty of Medicine, UI Medical Student : Faculty of Medicine

More information

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Placebo-Controlled Statin Trials Prevention Of CVD in Women MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

Get a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management

Get a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,

More information

Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP

Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular

More information

JAMA. 2011;305(24): Nora A. Kalagi, MSc

JAMA. 2011;305(24): Nora A. Kalagi, MSc JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for

More information

Acute Coronary Syndromes (ACS)

Acute Coronary Syndromes (ACS) Sally A. Arif, Pharm.D., BCPS (AQ Cardiology) Assistant Professor of Pharmacy Practice Midwestern University, Chicago College of Pharmacy Cardiology Clinical Specialist, Rush University Medical Center

More information

Cholesterol Treatment Update

Cholesterol Treatment Update Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:

More information

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016

More information

Pharmacy Drug Class Review

Pharmacy Drug Class Review Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES

More information

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure

More information

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology

More information

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence

Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University

More information

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This

More information

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi

More information

Rikshospitalet, University of Oslo

Rikshospitalet, University of Oslo Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular

More information

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

Pharmaceutical Help to Control Cholesterol

Pharmaceutical Help to Control Cholesterol Pharmaceutical Help to Control Cholesterol Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. Clinical Associate Professor, Univ. of Maryland This program has been brought to you by PharmCon

More information

1. Which one of the following patients does not need to be screened for hyperlipidemia:

1. Which one of the following patients does not need to be screened for hyperlipidemia: Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:

More information

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

Lipid is evolving. Dyslipidemia Vascular disease. Statin. Beyond 관동의대제일병원 내과박정배

Lipid is evolving. Dyslipidemia Vascular disease. Statin. Beyond 관동의대제일병원 내과박정배 Lipid is evolving Dyslipidemia Vascular disease Statin Beyond 관동의대제일병원 내과박정배 A Dyslipidemia 와혈관질환, 그연결고리는? & 약 80% 가 체내에서생성 약 20% 가 음식물에서흡수 Quantity of cholesterol in the body Bile acids 배설 동맥경화증의위험요인

More information

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE)

Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Ezetimibe and SimvastatiN in Hypercholesterolemia EnhANces AtherosClerosis REgression (ENHANCE) Thomas Dayspring, MD, FACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry

More information

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy

More information